u/HeavyCharge4647 · 16d agono track record yet
Anyone tracking CNTB?
CNTB is undervalued with multiple catalysts over the next 6-18 months: China approval of rademikibart could bring up to $110M in milestones plus royalties, FDA phase 3 alignment in asthma/COPD could validate the asset, and the drug's clean safety profile plus existing cash position and potential partnership interest suggest strong risk/reward at current valuation.